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Background: Evidence of the cost and effects of interventions for reducing the global burden of migraine remains
scarce. Our objective was to estimate the population-level cost-effectiveness of evidence-based migraine interventions
and their contributions towards reducing current burden in low- and middle-income countries.
Methods: Using a standard WHO approach to cost-effectiveness analysis (CHOICE), we modelled core set intervention
strategies for migraine, taking account of coverage and efficacy as well as non-adherence. The setting was primary
health care including pharmacies. We modelled 26 intervention strategies implemented during 10 years. These
included first-line acute and prophylactic drugs, and the expected consequences of adding consumer-education
and provider-training. Total population-level costs and effectiveness (healthy life years [HLY] gained) were combined
to form average and incremental cost-effectiveness ratios. We executed runs of the model for the general populations
of China, India, Russia and Zambia.
Results: Of the strategies considered, acute treatment of attacks with acetylsalicylic acid (ASA) was by far the most
cost-effective and generated a HLY for less than US$ 100. Adding educational actions increased annual costs by 1–2 US
cents per capita of the population. Cost-effectiveness ratios then became slightly less favourable but still less than US$
100 per HLY gained for ASA. An incremental cost of > US$ 10,000 would have to be paid per extra HLY by adding a
triptan in a stepped-care treatment paradigm. For prophylaxis, amitriptyline was more cost-effective than propranolol
or topiramate.
Conclusions: Self-management with simple analgesics was by far the most cost-effective strategy for migraine treatment
in low- and middle-income countries and represents a highly efficient use of health resources. Consumer education and
provider training are expected to accelerate progress towards desired levels of coverage and adherence, cost relatively
little to implement, and can therefore be considered also economically attractive. Evidence-based interventions
for migraine should have as much a claim on scarce health resources as those for other chronic, non-communicable
conditions that impose a significant burden on societies.
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Migraine is common in every part of the world [1]. The
Global Burden of Disease study 2010 (GBD 2010) found it
to be the third most prevalent disorder in the world and
among the top ten causes of years of healthy life lost to
disability (YLDs) [2]. Therapeutic options have increased
greatly over the last decades, but are not universally* Correspondence: mattias.linde@ntnu.no
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in any medium, provided the original work is pavailable. Economic evaluation can play a critical role not
only in identifying the most cost-effective migraine ther-
apies but also in demonstrating how health-care resource
allocation to migraine treatment might contribute to over-
all health gain.
The literature is unhelpful. A systematic review cap-
tured 21 cost-effectiveness analyses (CEAs) of migraine
interventions, with wide variation in the methods used
and results obtained [3]. Most studies (15/21) compared
different triptans. None studied over-the-counter (OTC)
drugs in monotherapy, which are by far the most used
treatments in all countries. Only four studies examinedOpen Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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the antiepileptic drugs, and only one provided a compari-
son with the prevailingly-used beta-blockers [4]. None has
looked beyond Europe and North America. Thus, the
cost-effectiveness is unknown of the most commonly used
drugs anywhere, and of all drugs in 90% of the world [5].
Our objective was to inform health policy by evaluating
the cost-effectiveness of a selected core set of interven-
tions for migraine in low- and middle-income countries.
Methods
We modelled costs and effects at population level in four
countries: three of the large, middle-income BRIC coun-
tries, Russia, India and China (excluding Brazil, for which
we had insufficient data), and one lower middle-income
country, Zambia, for comparison.
Selection of interventions
We adopted a core set of drug interventions, focusing
on those included in WHO’s Essential Medicines list
[6-8] but also those backed by substantial evidence of
effectiveness. We included first-line (simple analgesics,
eg, acetylsalicylic acid [ASA] 1,000 mg, but not para-
cetamol, for lack of evidence) and second-line medica-
tions (sumatriptan 50 mg because of its low price
compared to other triptans, and almotriptan 12.5 mg
because it had earlier been signified as the most cost-
effective triptan [9]) for acute treatment of attacks, and
assumed the latter would be used only by non-responders
to the former in a stepped-care treatment paradigm
(Table 1). We also included prophylactic drugs (propran-
olol 160 mg, topiramate 100 mg, amitriptyline 100 mg
daily). We followed guidelines for dosages [6,7]. We added
to the model the expected consequences of consumer
education (posters and leaflets in pharmacies explaining
how to acquire and best use these medications) and of
training of health-care providers.
Analytical model
We used the sectoral, population-based approach to
cost-effectiveness analysis (CEA) and the methods and
tools developed by WHO-CHOICE [14]. Specifically, we
ran a population model for two scenarios over a lifetime
analytical horizon (100 years) to give the total number of
healthy years lived by the population. Scenario 1 repre-
sented the natural history of migraine (no interventions
in place); scenario 2 reflected the population-level im-
pact of each specified intervention implemented for
10 years (thereafter, epidemiological variables and health-
state valuations returned to natural history values). The
difference between these two simulations represented the
population-level health gain (healthy life years [HLYs]
gained) from the intervention, relative to doing nothing.We applied separate disability weights (DWs) (health
state valuations on a 0–1 scale, where 1 equals full
health) to the times spent in the ictal (within-attack)
state of migraine and the interictal state (between at-
tacks, but susceptible). Ictal DW (0.43) was available
from GBD 2010 [2]. For interictal DW we applied the
lowest weighting of 0.01, and only to those with high-
frequency attacks. These DWs were multiplied by the es-
timated amounts of time spent in an ictal or interictal state
by persons with migraine, with and without intervention.
Analyses were limited to the population aged 18–65
years because neither efficacy nor epidemiological data
were reliably available for other age groups.
Epidemiological data
Sex-specific prevalences (Table 2) were drawn from epi-
demiological surveys performed in the four countries as
projects within the Global Campaign against Headache
by Lifting The Burden (LTB) [11,15-18]. The same
sources provided mean attack frequencies and dura-
tions (from which we calculated times spent in ictal
and interictal states).
Estimation of intervention effectiveness
We assessed the impact of acute management of mi-
graine – both with first-line (ASA) and with second-line
drugs (sumatriptan or almotriptan) for those not respond-
ing to the former – and its combination with a range of
prophylactic drugs (for high-frequency cases). For each
of these strategies, we also assessed the potential im-
pact of enhanced consumer education and provider
training on treatment adherence rates.
We modelled impact as reduction in total time spent
in the ictal state. For acute drugs, we used the clinical
endpoint of “sustained headache relief” (SHR), defined
as reduction in headache intensity from moderate or
severe to mild or none (which we assumed was not associ-
ated with disability [10] within 2 hours, without recur-
rence or further medication during 24 hours (Table 1).
We assumed baseline pain of migraine was always at
least moderate (Table 1 [11]). SHR therefore implied
full recovery of the remaining hours of the attack that
would have been spent with disability. We assumed that
treatment was taken at attack onset (Table 1), so that
hours recovered were attack duration minus 2 hours. We
obtained SHR values for each acute drug from systematic
literature reviews [19-21]. As these were based on clinical
trials reporting single doses, we assumed each acute medi-
cation was used once per attack (Table 1).
To enable an estimation of real-world effectiveness of
prophylactic drugs, data were collected only from trials
with a placebo-free baseline period and when fully re-
ported for a minimum of 100 representative and evalu-
able patients in the active treatment group [22-24]. The
Table 1 Assumptions made, how they were justified and their impact or weight in the model
Assumption Justification Impact or weight in the model
1 Mild headache is not associated with
disability
This was a standard assumption [10,2] If the assumption were false, the cost-effectiveness
of acute therapy would be slightly reduced
2 The pain associated with untreated
migraine is at least moderate
On the one hand, the diagnostic criteria
for migraine describe the pain as at least
moderate [11]; on the other hand, most
clinical trials have recruited patients with
at least moderate pain
None
3 In a stepped-care treatment paradigm,
triptans are used only by non-responders
to simple analgesics
This is the standard stepped-care
paradigm, in which more expensive
medications are reserved for those
shown to need them
The alternative would be a multiplicity of
scenarios of no obvious interest
4 Acute treatment is initiated at attack
onset (commencement of pain phase)
The assumption was necessary to
establish a time zero for purposes
of effect calculation and was subject
to further assumptions regarding
patient adherence (see below)
To the extent that the assumption was false,
effect and therefore cost-effectiveness would
be reduced
5 Each acute medication is used once
per attack
The assumption was necessary
because of dependence
on clinical trials data
Additional doses would increase cost,
particularly in the case of triptans
(mean number of triptan doses per
attack was reported as 1.4-1.5 in the
USA [12], but this may not be
representative of the countries
of interest)
6 The endpoint of sustained headache-relief
is an all-or-nothing response
The assumption is in line with the
standard definitions of pain relief
and sustained pain freedom [13]
The consequence of the assumption was an
underestimation of effectiveness
7 Prophylaxis is offered only to the
proportion of people with ≥3 migraine
attacks/month
As a recommendation based on
frequency only, this was
conservatively chosen [6]
This is a clinical rather than an economic
threshold, so it would be of limited interest
to vary it. Lowering the threshold to ≥2 would
increase the use of prophylactics with less
gain per user
8 ASA has high current coverage (80%)
in all study contexts except Zambia
(50%)
This was conservative; ASA is available
almost universally, but not easily in
rural Zambia
No impact on cost-effectiveness estimations.
Higher coverage would allow greater
population health gain
9 As a result of non-adherence, a
proportion of patients use OTC-drugs
later than is ideal, and in suboptimal
doses (described in the text).
Best estimate, formed from our
clinical judgement
Better adherence would lead to higher
health gain and therefore improve
cost-effectiveness
10 Provider adherence is 75% Best estimate, based on our experience Higher adherence would allow greater
population health gain, which would
improve cost-effectiveness estimations
11 Public education improves adherence
by 50% of the current deficit
Based on what can be in expected
in real world settings
A greater improvement of consumer
adherence would lead to improved
cost-effectiveness as well as greater
population health gain
12 Three-monthly doctor visits, each of
10 minutes’ duration, are needed for
monitoring and prescription of triptans
and prophylactics
Reflects typical clinical need and
treatment practice in these countries
More or longer visits would increase costs
13 For consumer education, the number
of leaflets needed is 50% of the disease
prevalence, and one poster is required
per 2,000 of the population
Leaflet numbers allows for high
circulation/exposure; poster numbers
conform to WHO programme
costing standards
Increasing or decreasing leaflet or poster
numbers would have a negligible impact
on base-line results because the base-line
cost of consumer education is very low
(US$ 0.01-0.02 per capita)
14 For provider education, one physician per
primary health-care centre per year will
be trained for one day
This represents an effective approach
to reaching primary health care
throughout the country
Increasing or decreasing the number of
trained providers would have a negligible
impact on base-line results because the
base-line cost of provider education is
very low (US$ 0.01-0.02 per capita)
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Table 2 Epidemiological data
Epidemiological variable Sub-group China India Russian Federation Zambia
Migraine prevalence (18–65 years) Male 5.4% 19.4% 12.6% 18.0%
Female 12.6% 32.8% 30.4% 27.1%
Case distribution (attacks per month) Low frequency [<3] 62% 63% 52% 50%
High frequency [≥3] 38% 37% 48% 50%
Mean attacks (per month) Low frequency 1.05 1.05 1.2 0.56
High frequency 5.65 4.59 6.4 3.94
Mean duration of attack (hours) All cases 23.4 13.1 15.0 36.4
Time spent in ictal state (per year) Low frequency 3.4% 1.9% 2.5% 2.8%
High frequency 18.1% 8.2% 13.2% 19.7%
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culated (Table 3). We assumed prophylaxis would be of-
fered only to the proportion of people with ≥3 migraine
attacks/month (Table 1), and derived this proportion for
each country from the LTB surveys (Table 2). The po-
tential effect of acute treatment was projected onto at-
tacks not averted by prophylaxis.
Estimates of efficacy obtained from clinical trials were
adjusted better to reflect effectiveness in the real world
by reference to treatment coverage (the proportion of
people in need of the treatment who receive it) and ad-
herence (Table 3). We assumed ASA had high current
coverage (80%) everywhere except in Zambia (50%)
(Table 1). We based estimates of triptan coverage on
sales data obtained from the Intercontinental Medical
Statistics (IMS) database: 2% for sumatriptan (Zambia
1%) and 0% for almotriptan in all countries modelled.
We set target coverage at 90% (Zambia 80%) for acute
drugs and at 30% (reflecting need limited to high-
frequency cases) for prophylactic drugs (Table 3).
To the extent that we could, we based estimates of
current patient adherence rates on a systematic literature
review. No evidence was found for patient adherence toTable 3 Efficacy, coverage and adherence values used in base
Intervention Efficacy Coverage
Current Ta
Drugs providing sustained headache relief
ASA 1,000 mg 39% [21] 80%
90
(Zambia 50%)
Sumatriptan 50 mg 35% [19] 2% (Z
(Zambia 1%)
Almotriptan 12.5 mg 45% [20] 0%
Drugs averting migraine attacks
Propranolol 160 mg 28% [22] 3% 30
Topiramate 100 mg 40% [23] 1%
Amitriptyline 100 mg 44% [24] 3%OTC-drugs in monotherapy, so 80% was used. This was
based on assumptions (Table 1) regarding the following
components of non-adherence: [I] Not taking the OTC-
drugs at all. Conceivably, this is true for 10% of patients
covered and thus contributing with 10% to a total percent-
age of OTC-drug non-adherence. [II] Taking OTC-drugs
too late (1 hour or more after onset). We assumed that
10% use it after 1 hour, another 10% use it after 2 hours,
another 10% after 3 hours, and another 10% after 4 hours.
They are losing an average of 2.5 hours from the possible
gain of 16.7 hours (global mean attack duration minus 2
hours). This contributes with 6% (40% of patients * 15% of
possible gain) non-adherence. [III] Using OTC-drugs in a
too low dose. We assumed that 10% use half of the dose.
Of them, probably one half has an effect, so this would
contribute with another 5% to the total OTC-drug non-
adherence. [IV] We assumed the model could not cope
with overusage, so that was ignored. For prescribed drugs
(triptans and prophylactics), we used the median current
patient adherence rate reported in the literature. This
was 56% for triptans [25-30], 71% for propranolol
(betablockers) [22,31-34], 60% for topiramate (antiepi-
leptics) [22,24,31,32,34-37], and 42% for amitriptyline-case analysis
Provider adherence Patient adherence
rget Current Target Current Target
%
100% 100% 80% 90%
ambia 80%) 75% 88% 56% 78%
75% 88% 56% 78%
% 75% 88% 71% 86%
75% 88% 60% 80%
75% 88% 42% 71%
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volved, we modelled the effects of each separately, im-
plying no interaction between adherences to each
component. There was no published evidence for pro-
vider adherence data. However, there was reason to say
it was not 100%. For triptans, we knew some physicians were
unduly cost-conscious (and limit supply inappropriately) and
that for prophylactics there was under-dosing (both correct-
able in theory through education). Therefore, we assumed
provider adherence to be 75% (Table 1). Target consumer
and provider adherence rates were calculated based on
the assumption that public education would not improve
adherence to 100% but by 50% of the current deficit
(Tables 1 and 3) [38-41].
Estimation of costs
We adopted an “ingredients” approach with a societal
perspective, including, as applicable, drug dosage and
frequency, primary-care visits, consumer education and
provider training. The base year was 2008, and the time
horizon used was 10 years of full implementation.
We obtained supplier prices for generically produced
drugs (Table 4) from the International Drug Price Indicator
Guide for 2008, adjusting to include domestic margin [42].
The cheapest retailer prices for drugs not in the guide
(sumatriptan, almotriptan and topiramate) were obtained
from the IMS database (third quarter 2007). For sumatriptan
(and topiramate in Russia), we used 2014 prices because of
price collapses. We imputed prices for countries where
drugs were not currently available. For acute medications,
we multiplied mean costs per attack by the number of at-
tacks per year in the country population to give the total
cost of the intervention per year of implementation.
We assumed that three-monthly doctor visits were
needed for monitoring and prescription of triptans and
prophylactics (Table 1). Unit-costs of primary-care ser-
vices were derived from an econometric analysis of a
multinational dataset of hospital costs, using gross na-
tional income per capita (plus other explanatory vari-
ables) to predict unit costs. The mean duration of a
doctor’s visit was defined as 10 minutes (Table 1).
For consumer education, we assumed the number of
leaflets needed was 50% of the disease prevalence, andTable 4 Drug prices (US$) used in base-case analysis
Drug Dose Source
ASA 500 mg International drug price indicator g
Propranolol 160 mg
Amitriptyline 100 mg
Topiramate 100 mg
Sumatriptan 50 mg IMS database
Almotriptan 12.5 mgone poster was required per 2,000 of the population
(Table 1). We applied WHO-CHOICE default prices to
leaflets and posters (and their associated distribution).
For provider education, we assumed that one physician
per primary health-care centre per year would be trained
for one day (Table 1).Results
Population-level health effects, costs and cost-effectiveness
of the different management strategies are reported for the
four countries in Table 5. Results are presented for speci-
fied levels of treatment coverage in the target population,
first at prevailing rates of patient and provider adherence,
then with improved rates of adherence that reflect the
addition of consumer education and provider training.Intervention effectiveness
The population-level health impact of these manage-
ment strategies, in terms of providing SHR or reducing
the frequency of migraine attacks, is quite considerable.
For example, and compared to no treatment, acute man-
agement with simple analgesics such as ASA annually
generates 530 extra HLYs per million population in
China and over 1,200 HLYs in Zambia and the Russian
Federation; this is as a result of the reduced amount of
time spent in a (highly disabling) ictal state. Additional
health gain (of an estimated 12.5%) could be realised by
enhancing consumer education and therefore adherence
to such non-specific drug treatment. The strategy associ-
ated with the greatest population-level health gain was
acute, stepped-care management using ASA plus suma-
triptan for non-responders, together with consumer edu-
cation and provider training (across the four countries,
700–1,600 HLYs gained per one million population). A
combination of acute management and prophylaxis
(with amitriptyline) also produces sizeable health bene-
fits, but produces less overall gain in the population
because of lower expected coverage and applicability (a
sub-population of high frequency migraine cases).
Amitriptyline was used in the main analysis because it
is considerably more effective than propranolol (Table 3)
and also far cheaper than topiramate (Table 4).China India Russia Zambia
uide $ 0.004 $ 0.004 $ 0.004 $ 0.004
$ 0.005 $ 0.005 $ 0.005 $ 0.005
$ 0.006 $ 0.006 $ 0.006 $ 0.006
$ 0.13 $ 0.03 $ 0.12 $ 0.133
$ 0.81 $ 0.11 $ 1.07 $ 0.66
$ 5.19 $ 5.19 $ 5.19 $ 5.19
Table 5 Health effects, costs and cost effectiveness of migraine management strategies in China, India, Russian Federation and Zambia
China India
Target
coverage*
Healthy life years
gained per year
(per 1 m popn)
Cost per year
per capita (US$)
Cost per healthy
life year gained
(US$)
ICER
(US$)
Healthy life years
gained per year
(per 1 m popn)
Cost per year per
capita (US$)
Cost per healthy life
year gained (US$)
ICER
(US$)
A. ACUTE MANAGEMENT (NON-SPECIFIC DRUGS)
Simple analgesics
(e.g. ASA 1 g)
90% 530 $ 0.02 $ 34 $ 35 673 $ 0.05 $ 73 $ 75
With consumer education 597 $ 0.03 $ 53 $ 204 757 $ 0.06 $ 77 $ 105
B. ACUTE MANAGEMENT (SPECIFIC DRUGS)
Sumatriptan (50 mg) 90% 152 $ 2.14 $ 14,061 193 $ 1.20 $ 6,201
With consumer education 212 $ 2.16 $ 10,159 269 $ 1.21 $ 4,485
With provider training 178 $ 2.16 $ 12,129 226 $ 1.20 $ 5,335
With consumer education
and provider training
248 $ 2.17 $ 8,762 314 $ 1.21 $ 3,859
Almotriptan (12.5 mg) 90% 196 $ 5.59 $ 28,546 249 $ 14.55 $ 58,533
With consumer education 273 $ 5.61 $ 20,544 346 $ 14.56 $ 42,049
With provider training 229 $ 5.61 $ 24,528 290 $ 14.56 $ 50,187
With consumer education
and provider training
318 $ 5.62 $ 17,652 404 $ 14.56 $ 36,053
C. ACUTE STEPPED CARE MANAGEMENT
ASA (1 g) + sumatriptan
(50 mg)
90% 431 $ 2.52 $ 5,840 547 $ 1.62 $ 2,964
With consumer education 600 $ 2.53 $ 4,215 761 $ 1.63 $ 2,139
With provider training 503 $ 2.53 $ 5,033 638 $ 1.62 $ 2,548
With consumer education
and provider training
700 $ 2.54 $ 3,633 $ 24,271 888 $ 1.63 $ 1,839 $ 11,996
D. PROPHYLAXIS + ACUTE MANAGEMENT
ASA (1 g) + amitriptyline
(100 mg)
30% 112 $ 0.18 $ 1,649 145 $ 0.26 $ 1,795
With consumer education 189 $ 0.20 $ 1,047 245 $ 0.27 $ 1,098
With provider training 130 $ 0.20 $ 1,517 169 $ 0.26 $ 1,565
With consumer education
and provider training
220 $ 0.21 $ 959 286 $ 0.27 $ 957
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Table 5 Health effects, costs and cost effectiveness of migraine management strategies in China, India, Russian Federation and Zambia (Continued)
Sumatriptan (50 mg) +
amitriptyline (100 mg)
30% 49 $ 0.73 $ 14,872 63 $ 0.53 $ 8,329
With consumer education 83 $ 0.74 $ 8,962 107 $ 0.54 $ 5,010
With provider training 68 $ 0.74 $ 10,908 88 $ 0.53 $ 6,049
With consumer education
and provider training
115 $ 0.76 $ 6,571 149 $ 0.54 $ 3,637
ASA + sumatriptan +
amitriptyline
30% 103 $ 0.80 $ 7,740 133 $ 0.73 $ 5,467
With consumer education 174 $ 0.81 $ 4,657 226 $ 0.74 $ 3,273
With provider training 143 $ 0.81 $ 5,668 185 $ 0.73 $ 3,961
With consumer education
and provider training
241 $ 0.82 $ 3,409 313 $ 0.74 $ 2,371
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Russian Federation Zambia
Russian Federation Zambia
Cost per year per
capita (US$)
Cost per healthy
life
year gained (US
$)
ICER
(US$)
Healthy life years
gained per year
(per 1 m popn)
Cost per year per
capita (US$)
Cost per healthy
life year gained
(US$)
ICER
(US$)
Healthy life years
gained per year
(per 1 m popn)
A. ACUTE MANAGEMENT (NON-SPECIFIC DRUGS)
Simple analgesics
(e.g. ASA 1 g)
1223 $ 0.07 $ 53 $ 63 1244 $ 0.03 $ 24 $ 24
With consumer education 1376 $ 0.19 $ 136 $ 801 1400 $ 0.12 $ 85 $ 575
B. ACUTE MANAGEMENT (SPECIFIC DRUGS)
Sumatriptan (50 mg) 352 $ 12.55 $ 35,684 358 $ 2.62 $ 7,330
With consumer education 490 $ 12.67 $ 25,869 498 $ 2.71 $ 5,442
With provider training 410 $ 12.64 $ 30,804 417 $ 2.64 $ 6,329
With consumer education
and provider training
571 $ 12.76 $ 22,330 581 $ 2.73 $ 4,698
Almotriptan (12.5 mg) 452 $ 23.38 $ 51,728 460 $ 8.82 $ 19,187
With consumer education 630 $ 23.51 $ 37,332 640 $ 8.91 $ 13,915
With provider training 527 $ 23.47 $ 44,508 536 $ 8.84 $ 16,482
With consumer education
and provider training
735 $ 23.60 $ 32,121 747 $ 8.93 $ 11,953
C. ACUTE STEPPED CARE MANAGEMENT
ASA (1 g) + sumatriptan
(50 mg)
994 $ 15.71 $ 15,811 1011 $ 2.95 $ 2,917
With consumer education 1384 $ 15.84 $ 11,440 1408 $ 3.04 $ 2,158
With provider training 1160 $ 15.80 $ 13,630 1179 $ 2.97 $ 2,517
With consumer education
and provider training
1615 $ 15.93 $ 9,861 $ 65,920 1643 $ 3.06 $ 1,861 $ 12,102
D. PROPHYLAXIS + ACUTE MANAGEMENT
ASA (1 g) + amitriptyline
(100 mg)
275 $ 1.45 $ 5,264 305 $ 0.24 $ 773
With consumer education 465 $ 1.57 $ 3,377 515 $ 0.32 $ 631
With provider training 321 $ 1.54 $ 4,790 355 $ 0.25 $ 716
With consumer education
and provider training
543 $ 1.66 $ 3,059 601 $ 0.34 $ 573
Table 5 Health effects, costs and cost effectiveness of migraine management strategies in China, India, Russian Federation and Zambia
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Table 5 Health effects, costs and cost effectiveness of migraine management strategies in China, India, Russian Federation and Zambia (Continued)
Sumatriptan (50 mg) +
amitriptyline (100 mg)
121 $ 3.95 $ 32,633 134 $ 1.09 $ 8,102
With consumer education 205 $ 4.07 $ 19,902 227 $ 1.18 $ 5,188
With provider training 168 $ 4.04 $ 24,027 186 $ 1.11 $ 5,937
With consumer education
and provider training
284 $ 4.16 $ 14,644 315 $ 1.19 $ 3,796
ASA + sumatriptan +
amitriptyline
248 $ 4.55 $ 18,319 275 $ 1.20 $ 4,362
With consumer education 420 $ 4.67 $ 11,128 465 $ 1.29 $ 2,773
With provider training 345 $ 4.64 $ 13,449 382 $ 1.22 $ 3,191
With consumer education
and provider training
583 $ 4.76 $ 8,166 645 $ 1.31 $ 2,026
*Target coverage for acute management in Zambia set at 80%.
ICER=Incremental cost-effectiveness ratio. All interventions without an ICER value are 'dominated’.
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The annual cost of different management strategies varies
enormously, from just a few US cents up to US$ 5–25 per
capita population (for almotriptan). This is essentially
driven by the price of drugs (over US$ 5 per 12.5 mg tablet
of almotriptan, compared to < 1 US cent for a 1,000 mg
dose of ASA). For sumatriptan, the price (and therefore
overall cost of treatment) is more variable: for example it is
about ten times higher in Russia than in India. Evidently,
the addition of consumer education and provider training
strategies increases the cost of care, but only to a fixed and
small degree (of 1–2 US cents per head of population).
Dividing the total cost of each intervention by its asso-
ciated health benefit provides a measure of its cost-
effectiveness, relative to a situation of no treatment.
Table 5 shows that the cost per HLY gained ranges from
less than US$ 100 (for acute management with simple
analgesics) to thousands or even tens of thousands of US
dollars (for treatment of analgesic non-responders with
triptans). By far the most cost-effective strategy is acute
management with simple analgesics (ranging between
US$ 24–73 per HLY gained across the four countries);
adding in consumer education and thereby improving ad-
herence has a small upward influence on cost-effectiveness
ratio; compared to no treatment at all, this strategy falls
below US$ 150 per HLY gained, but compared to use of
simple analgesics without consumer education, the incre-
mental cost to be paid in order to obtain one extra HLY
rises to US$ 200–800. Beyond that, the aforementioned
stepped-care strategy using both specific and non-specific
drugs as well as consumer education and provider training
would further increase population-health gain but at an in-
cremental cost that is expected to fall outside national
thresholds for value for money in the health sector (that is,
each additional HLY comes at an extra cost of many
times the average income per person). Finally, combin-
ing prophylaxis (with amitriptyline) and acute manage-
ment (with ASA) presents a favourable ratio of cost to
effect when compared to no treatment, particularly if
accompanied by consumer education and provider
training (below US$ 600 per HLY gained in Zambia,
and below US$ 1,000 in China and India); in incremen-
tal cost-effectiveness terms, however, it is ‘dominated’
by the superior cost-effectiveness profile of acute man-
agement with simple analgesics alone.
Sensitivity and uncertainty analyses
A series of sensitivity and uncertainty analyses were car-
ried out in order to examine the impact of plausible
levels of variability around baseline estimates. The re-
sults of these analyses demonstrate that, even after
allowing for this variability, acute management with sim-
ple analgesics (with or without consumer education)
continues to be easily the most cost-effective strategy forreducing the burden of migraine in lower middle- and
middle-income countries. We assessed a) the impact of
changes in underlying analytical choices (such as whether
to discount health gains or not), b) the influence of specific
input parameters on costs and effects (such as drug prices
and disability weights), and c) the potential variability
around total costs and effects of different interventions.
Baseline results did not employ discounting or age-
weighting of health benefits. Discounting health gains
over time (by a factor of 3%) increased average cost-
effectiveness ratios by 18%; application of an age-weighting
function – which places a higher value on health gains in
middle aged groups and less for the old and young – on
top of discounting has a negligible impact on baseline cost-
effectiveness results (<5%).
The most sensitive price in the analysis was sumatrip-
tan. Reducing the applicable price of sumatriptan in each
country by 50% has a sizeable impact on the cost and
cost-effectiveness profile for this drug (reducing baseline
cost-effectiveness ratios [CERs] by 30-40%), but not
enough to bring it close to simple analgesics.
Concerning disability weights, there was a question of
what disability weight to use – if any – for the interictal
state; accordingly we assessed the impact on health ef-
fects and cost-effectiveness ratios of using no disability
weight and a higher disability weight (0.03), compared to
the baseline value of 0.01. Use of a zero disability weight
resulted in slightly higher health effects (5%) and therefore
marginally better cost-effectiveness ratios (4% lower).
The higher disability weight led to less overall health
gain (7%) and correspondingly worse cost-effectiveness
ratios (8% higher).
In order to assess the inherent uncertainty around
(point) estimates of total intervention costs and health
effects, a subset of intervention strategies were entered
into an analytical software package (MCLeague), which
performs a probabilistic uncertainty analysis using Monte
Carlo simulation (1,000 runs were made, using a truncated
normal distribution). A subset was chosen for the sake of
being able to visualise the results in cloud graph format.
The seven selected interventions were ASA + consumer
education and all other drug interventions that included
consumer education and provider training (since the latter
gave better cost-effectiveness ratios than intervention sce-
narios without one or both of these additional compo-
nents). We used a coefficient of variation of 0.2 for effects
and 0.25 for costs. The graphical results presented in
Figure 1 relate to China and demonstrate that, even
after allowing for this variability, the average cost-
effectiveness ratios of interventions for ASA + consumer
education do not overlap appreciably with other interven-
tions, confirming its clear superiority in cost-effectiveness
terms. It also shows that after allowing for uncertainty, the
stepped-care strategy using both specific and non-specific
Figure 1 Uncertainty cloud graph for migraine interventions, China.
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training is the next most cost-effective strategy after
ASA + consumer education, but incurs significantly
greater costs to achieve the same level of population
health gain. Similar results pertain to the other coun-
tries in the analysis.
Discussion and conclusions
Acute treatment of migraine attacks with simple anal-
gesics (in this analysis, ASA) generated a whole year of
healthy life for less than US$ 100. This means that it is
among the most efficient interventions to improve
population health. The context in which this finding
must be set is that migraine is the third most prevalent
disease in the world, and the seventh highest specific
cause of global disability [2,43]. In other words, evidence-
based interventions for migraine should have as much a
claim on scarce health resources as other chronic, non-
communicable conditions that impose a substantial
burden on societies, and a greater claim than many.
The potential for health gain in society is huge. In
three of the countries in question (Russia [15], India
and Zambia [data from LTB, submitted for publication]),
the 1-year prevalence of migraine (range 20.3-25.6%)
is well-above the global mean of 14.7% [2]. Not only is
the cost of this intervention low, but also there is little
requirement for health-service infrastructural support
that might be a barrier to its implementation or prevent
widespread coverage.
Simple analgesics are not of course the complete
answer to migraine: they have limited efficacy (39% SHR
was built into the model, implying no benefit for 61%).
In migraine management following European guidelines,prescription drugs are called in as reinforcements only
when needed, in a stepped-care paradigm [6,7]. Pre-
scribed drugs, as second-line in acute treatment or for
prophylaxis, are less cost-effective in our model but not
necessarily with an unfavourable ratio of cost to effect
when compared with many other interventions aimed at
improving population health. We showed that training
primary care doctors in the management of migraine
is likely to increase the cost-effectiveness of drugs on
prescription. We further showed that the incremental
health benefits obtained from adding educational pro-
grammes were achieved at acceptable incremental costs.
Even if marginally less cost-effective, strategies with edu-
cational programmes may be worth investing in, since
the absolute health-gain is higher with their inclusion.
Incorporating the effects of consumer education (posters
and leaflets in pharmacies) on coverage was a major strength
of our model.
These are entirely new findings. There is no earlier
evidence on the cost-effectiveness of OTC drugs alone
for migraine even though, worldwide, the great majority
of people with headache are primarily self-treating [1].
Efficacy data for prophylactic drugs, mainly from older
clinical trials, relate to a change from a placebo run-in
period, which underestimates their real-world effect.
We selectively used data from trials with a placebo-free
run-in period to avoid this. Furthermore, we modelled
the impact of non-adherence to provide more realistic
estimates. The finding that amitriptyline was more likely
to be cost-effective than propranolol is concordant with
that of Yu et al. 2010 [4]. Of the few other, earlier CEAs
of prophylactic migraine drugs, all were restricted to
antiepileptic drugs [44-46].
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lation and costing models rest upon a series of best esti-
mates, including the expected patterns of resource use
and, perhaps most importantly, estimates of intervention
efficacy. Those drawn from trials were derived in western
countries, with uncertain application to the countries
in question. Not including paracetamol was a limitation
forced on us because the only evidence available was from
42 highly atypical US patients, from which we felt unable
to extrapolate to these countries [47]. Even though the in-
direct costs of migraine dwarf the direct costs, productiv-
ity gains and time costs were not taken into consideration
because no internationally agreed approach is yet available
to measure these satisfactorily [5].
Despite these limitations, the study has provided infor-
mation that should greatly assist regional health-policy
makers, in rich and poor countries alike, in allocating
fixed health budgets between interventions and between
health sectors in order to maximize health in society.
What are needed now are CEAs on interventions for
headache disorders more broadly, rather than migraine
alone, which in real life is not treated in isolation. These
include structured headache services, ideally provided at
national level, with quality evaluation, and particularly
interventions with a substantial educational element
[48-50]. Many such initiatives are being pursued by LTB
within the Global Campaign against Headache [17].
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